Effectiveness of inhibitor mTOR in patients with lymphangioleiomyomatosis.

Novikova, Lubov; Ilkovich, Mihail; Dzadzua, Dali; Baranova, Olga; Vasilyeva, M. V.

doi:10.1183/13993003.congress-2018.pa2240

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Published data on pregnancy outcomes in ILD patients are limited, include small sample sizes between 9 to 15 pregnancies, and have mixed results (4)(5)(6)(7). From a pulmonary standpoint, it is hypothesized that women with ILD may have decreased arterial oxygen saturation due to parenchymal fibrosis in the setting of increased oxygen demand during pregnancy.…”

Section: Introductionmentioning

confidence: 99%

Pregnancy Outcomes in Patients With Interstitial Lung Disease

Clowse

Rajendran

Eudy

et al. 2023

Arthritis Care & Research

View full text Add to dashboard Cite

Objective Women with interstitial lung disease (ILD) are recommended to avoid pregnancy based on limited data. This study seeks to determine maternal and pregnancy outcomes in the largest‐to‐date cohort of patients with ILD. Methods Medical records in the Duke University Health System were reviewed for pregnancies in patients with a diagnosis of ILD with underlying autoimmune disease. Pregnancies were classified as having very severe, severe, mild‐moderate, or normal lung function based on pulmonary function tests (PFTs). Adverse pregnancy outcomes (APOs) were defined using the Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus and Antiphospholipid Syndrome APO (PROMISSE‐APO) and Severe PROMISSE‐APO criteria. Results Among 86 pregnancies in 60 women, 85% women were Black, 71% had sarcoidosis, and 29% had connective tissue disease (CTD)–associated ILD (CTD‐ILD). Of the pregnancies with available PFTs (n = 59), 12% had very severe ILD, 25% had severe ILD, 51% had mild‐moderate ILD, and 12% had normal lung function. PROMISSE‐APOs occurred in 32% of pregnancies, including all pregnancies with very severe ILD (P = 0.02 across severity groups), 56% of pregnancies with CTD‐ILD, and 23% with sarcoidosis (P = 0.02). Severe PROMISSE‐APOs occurred in 15% of pregnancies, including 60% with very severe ILD and 28% with CTD‐ILD. There were no maternal deaths. One woman required an intensive care hospital stay during pregnancy. Three women had volume overload after delivery that resolved with medical management. Seven women received oxygen during delivery, although none were intubated. Conclusion Although APOs were common in women with very severe ILD and underlying CTD, overall maternal morbidity and mortality were low. These data suggest women with ILD may be able to safely attempt pregnancy.

show abstract

Section: Introductionmentioning

confidence: 99%

Pregnancy Outcomes in Patients With Interstitial Lung Disease

Clowse

Rajendran

Eudy

et al. 2023

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…Higher levels of VEGF-D (area under the curve (AUC) 0.833), MMP-2 (AUC 0.756) and MMP-7 (AUC 0.820) were predictive of LAM diagnosis. N ovikova et al [81] reported on the use of mammalian target of rapamycin (mTOR) inhibitors in 15 patients with progressive LAM and showed a decrease of abdominal leiomyomas in three patients, with no cases of pneumo-, chylo- or haemothorax, suggesting treatment efficacy.…”

Section: Introductionmentioning

confidence: 99%

Research highlights from the 2018 ERS International Congress: interstitial lung diseases

et al. 2019

View full text Add to dashboard Cite

This article reviews a selection of the scientific presentations on interstitial lung disease (ILD)/diffuse parenchymal lung disease (DPLD) that were made at the 2018 European Respiratory Society (ERS) International Congress in Paris. A number of advances in the epidemiology, pathogenesis, diagnosis and treatment of these disorders were presented and discussed by clinicians and researchers. The research topics span over all four groups of ERS Assembly 12: Interstitial Lung Diseases (Group 12.01: Idiopathic interstitial pneumonias; Group 12.02: ILD/DPLD of known origin; Group 12.03: Sarcoidosis and other granulomatous ILD/DPLD; Group 12.04: Rare ILD/DPLD).

show abstract

Effectiveness of inhibitor mTOR in patients with lymphangioleiomyomatosis.

Cited by 2 publications

References 0 publications

Pregnancy Outcomes in Patients With Interstitial Lung Disease

Pregnancy Outcomes in Patients With Interstitial Lung Disease

Research highlights from the 2018 ERS International Congress: interstitial lung diseases

Contact Info

Product

Resources

About